Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 201

1.

[Medication of the month. Ticagrelor (Brilique): potent oral antagonist of platelet activity].

Lancellotti P.

Rev Med Liege. 2012 Sep;67(9):485-91. French.

PMID:
23115850
[PubMed - indexed for MEDLINE]
2.

Pharmacokinetic, pharmacodynamic and pharmacogenetic profile of the oral antiplatelet agent ticagrelor.

Teng R.

Clin Pharmacokinet. 2012 May 1;51(5):305-18. doi: 10.2165/11630960-000000000-00000. Review.

PMID:
22489610
[PubMed - indexed for MEDLINE]
3.

Ticagrelor: oral reversible P2Y(12) receptor antagonist for the management of acute coronary syndromes.

Cheng JW.

Clin Ther. 2012 Jun;34(6):1209-20. doi: 10.1016/j.clinthera.2012.04.005. Epub 2012 Apr 21. Review.

PMID:
22521881
[PubMed - indexed for MEDLINE]
4.

Ticagrelor: a review of its use in the management of acute coronary syndromes.

Deeks ED.

Drugs. 2011 May 7;71(7):909-33. doi: 10.2165/11206850-000000000-00000. Review.

PMID:
21568367
[PubMed - indexed for MEDLINE]
5.

Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?

Kowalczyk M, Banach M, Mikhailidis DP, Hannam S, Rysz J.

Med Sci Monit. 2009 Dec;15(12):MS24-30. Review.

PMID:
19946242
[PubMed - indexed for MEDLINE]
6.

Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.

James S, Akerblom A, Cannon CP, Emanuelsson H, Husted S, Katus H, Skene A, Steg PG, Storey RF, Harrington R, Becker R, Wallentin L.

Am Heart J. 2009 Apr;157(4):599-605. doi: 10.1016/j.ahj.2009.01.003.

PMID:
19332184
[PubMed - indexed for MEDLINE]
7.

Evaluating the risk-benefit profile of the direct-acting P2Y(12) inhibitor ticagrelor in acute coronary syndromes.

Husted S.

Postgrad Med. 2011 Nov;123(6):79-90. doi: 10.3810/pgm.2011.11.2498. Review.

PMID:
22104457
[PubMed - indexed for MEDLINE]
8.

Ticagrelor in ST-elevation myocardial infarction.

Sgueglia GA, Tarantini G, Niccoli G.

Curr Vasc Pharmacol. 2012 Jul;10(4):458-62. Review.

PMID:
22339257
[PubMed - indexed for MEDLINE]
9.

Novel antiplatelet agent ticagrelor in the management of acute coronary syndrome.

Ramaraj R, Movahed MR, Hashemzadeh M.

J Interv Cardiol. 2011 Jun;24(3):199-207. doi: 10.1111/j.1540-8183.2010.00613.x. Epub 2010 Dec 28. Review.

PMID:
21198849
[PubMed - indexed for MEDLINE]
10.

Emerging oral antiplatelet therapies for acute coronary syndromes.

Pollack CV Jr.

Hosp Pract (1995). 2010 Nov;38(4):29-37. doi: 10.3810/hp.2010.11.337.

PMID:
21068524
[PubMed - indexed for MEDLINE]
11.

Lessons from platelet inhibition and patient outcomes.

Held C.

Curr Opin Cardiol. 2012 Jul;27(4):355-60. doi: 10.1097/HCO.0b013e328353fe7e.

PMID:
22565140
[PubMed - indexed for MEDLINE]
12.

Ticagrelor versus clopidogrel in patients with acute coronary syndromes.

Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA; PLATO Investigators, Freij A, Thorsén M.

N Engl J Med. 2009 Sep 10;361(11):1045-57. doi: 10.1056/NEJMoa0904327. Epub 2009 Aug 30.

PMID:
19717846
[PubMed - indexed for MEDLINE]
Free Article
13.

Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist.

Husted S, van Giezen JJ.

Cardiovasc Ther. 2009 Winter;27(4):259-74. doi: 10.1111/j.1755-5922.2009.00096.x. Review.

PMID:
19604248
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Ticagrelor: an investigational oral antiplatelet treatment for reduction of major adverse cardiac events in patients with acute coronary syndrome.

Abergel E, Nikolsky E.

Vasc Health Risk Manag. 2010 Oct 21;6:963-77. doi: 10.2147/VHRM.S13263. Review.

PMID:
21057581
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Ticagrelor: a novel reversible oral antiplatelet agent.

Nawarskas JJ, Clark SM.

Cardiol Rev. 2011 Mar-Apr;19(2):95-100. doi: 10.1097/CRD.0b013e3182099d86. Review.

PMID:
21285670
[PubMed - indexed for MEDLINE]
16.

Efficacy and safety of ticagrelor: a reversible P2Y12 receptor antagonist.

Anderson SD, Shah NK, Yim J, Epstein BJ.

Ann Pharmacother. 2010 Mar;44(3):524-37. doi: 10.1345/aph.1M548. Epub 2010 Feb 2. Review.

PMID:
20124464
[PubMed - indexed for MEDLINE]
17.

Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study.

Kohli P, Wallentin L, Reyes E, Horrow J, Husted S, Angiolillo DJ, Ardissino D, Maurer G, Morais J, Nicolau JC, Oto A, Storey RF, James SK, Cannon CP.

Circulation. 2013 Feb 12;127(6):673-80. doi: 10.1161/CIRCULATIONAHA.112.124248. Epub 2012 Dec 31.

PMID:
23277305
[PubMed - indexed for MEDLINE]
Free Article
18.

Aspirin, clopidogrel, and ticagrelor in acute coronary syndromes.

Berger JS.

Am J Cardiol. 2013 Sep 1;112(5):737-45. doi: 10.1016/j.amjcard.2013.04.055. Epub 2013 Jun 7. Review.

PMID:
23751937
[PubMed - indexed for MEDLINE]
19.

Ticagrelor: from discovery to Phase III clinical trial.

Siller-Matula JM, Jilma B.

Future Cardiol. 2010 Nov;6(6):753-64. doi: 10.2217/fca.10.89. Review.

PMID:
21142630
[PubMed - indexed for MEDLINE]
20.

Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial.

Becker RC, Bassand JP, Budaj A, Wojdyla DM, James SK, Cornel JH, French J, Held C, Horrow J, Husted S, Lopez-Sendon J, Lassila R, Mahaffey KW, Storey RF, Harrington RA, Wallentin L.

Eur Heart J. 2011 Dec;32(23):2933-44. doi: 10.1093/eurheartj/ehr422. Epub 2011 Nov 16. Erratum in: Eur Heart J. 2012 Nov;33(21):2750.

PMID:
22090660
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk